Savolitinib for Treating Brain and Leptomeningeal Metastases in Non-Small Cell Lung Cancer: A Case Study

1

METex14 skipping mutations occur in 3%-4% of NSCLC cases, but are less common in patients with brain or leptomeningeal metastases.
2

Savolitinib, a MET TKI, showed significant clinical benefit in a 66-year-old NSCLC patient with METex14 mutations and CNS metastases.
3

Next-generation sequencing of CSF identified METex14 mutations, highlighting its role in understanding tumor heterogeneity in CNS metastases.
4

The patient experienced an intracranial partial response and improved performance status after treatment with savolitinib.
5

This case suggests savolitinib may be a promising treatment option for NSCLC patients with CNS metastases harboring METex14 mutations.

1